HomeInsightsPE

Glaxosmithkline Pharmaceuticals Ltd PE Ratio

Glaxosmithkline Pharmaceuticals Ltd PE Ratio

stocks purchased

₹ 0.6 Cr

Volume Transacted

(Dec 12, 2024)

stocks purchased

2.4 K

Stocks Traded

(Dec 12, 2024)

Last Updated on: Dec 12, 2024

Image

Glaxosmithkline Pharmaceuticals Ltd

NSE: GLAXO

PE

48.7

Last updated on: Dec 12, 2024

Key Highlights

  • The P/E Ratio of Glaxosmithkline Pharmaceuticals Ltd is 48.7 as of 12 Dec 15:30 PM .
  • The P/E Ratio of Glaxosmithkline Pharmaceuticals Ltd changed from 49.4 on March 2019 to 55.8 on March 2024 . This represents a CAGR of 2.05% over 6 years.
  • The Latest Trading Price of Glaxosmithkline Pharmaceuticals Ltd is ₹ 2306 as of 12 Dec 15:30 .
  • The PE Ratio of Pharmaceuticals Industry has changed from 28.2 to 27.1 in 5 years. This represents a CAGR of -0.79%.
  • The PE Ratio of Automobile industry is 20.3. The PE Ratio of Finance industry is 17.8. The PE Ratio of IT - Software industry is 30.5. The PE Ratio of Pharmaceuticals industry is 40.0. The PE Ratio of Retail industry is 157.6. The PE Ratio of Textiles industry is 37.6 in 2024.

Historical P/E Ratio of Glaxosmithkline Pharmaceuticals Ltd

No data available

Company Fundamentals for Glaxosmithkline Pharmaceuticals Ltd

No data available

Image

Glaxosmithkline Pharmaceuticals Ltd

NSE: GLAXO

Share Price

₹ 2306.65

-38.80 (-1.65%)

stock direction

Last updated on: Dec 12, 2024

Market Price of Glaxosmithkline Pharmaceuticals Ltd

1M

1Y

3Y

5Y

Monitoring Glaxosmithkline Pharmaceuticals Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
12 Dec 20242306.65
11 Dec 20242345.45
10 Dec 20242328.95
09 Dec 20242328.2
06 Dec 20242346.4
05 Dec 20242377.1
04 Dec 20242401.7
03 Dec 20242422.1
02 Dec 20242409.25
29 Nov 20242445.7

SWOT Analysis Of Glaxosmithkline Pharmaceuticals Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Glaxosmithkline Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

Asset Value vs Market Value of Glaxosmithkline Pharmaceuticals Ltd

Market Value

0

Asset Value

0

* All values are in Rupees

Competitive Comparison of P/E Ratio

Key Valuation Metric of Glaxosmithkline Pharmaceuticals Ltd

No data available

No data available

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

Historical Market Cap of Glaxosmithkline Pharmaceuticals Ltd

No data available

* All values are in crore

Historical Revenue of Glaxosmithkline Pharmaceuticals Ltd

No data available

* All values are in crore

Historical EBITDA of Glaxosmithkline Pharmaceuticals Ltd

No data available

* All values are in crore

Historical Net Profit of Glaxosmithkline Pharmaceuticals Ltd

No data available

* All values are in crore

Historical Dividend Payout of Glaxosmithkline Pharmaceuticals Ltd

No data available

* All values are in %

About Glaxosmithkline Pharmaceuticals Ltd

  • GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma company to unite science, technology and talent to get ahead of disease together.
  • The Company is headquartered in Mumbai and it has six branch offices, a manufacturing facility at Nashik in Maharashtra, 22 contract manufacturing organisations (CMOs) with regional and sales hubs across India.
  • The Company is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals. The Company's portfolio includes General Medicines, Vaccines and Specialty medicines that help prevent and treat disease.
  • Their prescription medicines range across therapeutic areas, such as Anti-Infectives, Dermatology, Gynaecology, Diabetes, Oncology, Cardiovascular Disease and Respiratory Diseases.

Glaxosmithkline Pharmaceuticals Ltd News Hub

News

Glaxosmithkline Pharmaceuticals consolidated net profit rises 37.87% in the June 2024 quarter

Net profit of Glaxosmithkline Pharmaceuticals rose 37.87% to Rs 182.33 crore in the quarte...

Read more

2024-08-05 00:00:00

News

GSK Pharma Q1 PAT climbs 39% YoY to Rs 182 crore

Revenue from operations grew by 9.89% year on year (YoY) to Rs 811 crore during the quarte...

Read more

2024-08-03 00:00:00

News

GlaxoSmithKline Pharmaceuticals to declare Quarterly Result

GlaxoSmithKline Pharmaceuticals will hold a meeting of the Board of Directors of the Compa...

Read more

2024-10-25 00:00:00

News

Board of GlaxoSmithKline Pharmaceuticals recommends Special Interim Dividend

GlaxoSmithKline Pharmaceuticals announced that the Board of Directors of the Company at it...

Read more

2024-10-29 00:00:00

Product Composition

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

Data not available

FAQs for PE of Glaxosmithkline Pharmaceuticals Ltd

What is the current PE Ratio of Glaxosmithkline Pharmaceuticals Ltd?

The Current PE Ratio of Glaxosmithkline Pharmaceuticals Ltd is 48.74 as on 12 Dec 2024.

What is the average PE Ratio of the Pharmaceuticals industry?

The average industry PE Ratio of Pharmaceuticals is 40.0 as on 12 Dec 2024.

What was the PE Ratio of Glaxosmithkline Pharmaceuticals Ltd last year?

The PE Ratio of Glaxosmithkline Pharmaceuticals Ltd was 36.73 last year, now the PE ratio is 48.74, showing a year-on-year growth of 32.7%.

What does the PE Ratio of Glaxosmithkline Pharmaceuticals Ltd indicate about its stock?

The PE Ratio of Glaxosmithkline Pharmaceuticals Ltd is 48.74. This ratio indicates that investors are willing to pay 48.74 times the earnings per share for each share of Glaxosmithkline Pharmaceuticals Ltd.

What is the PE Ratio Growth of Glaxosmithkline Pharmaceuticals Ltd in comparison to its Earnings per Share (EPS) growth rate?

The PE Ratio of Glaxosmithkline Pharmaceuticals Ltd grew by 32.7% whereas, the EPS ratio grew by 36.3.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Demat Account
Verify your phone
+91
*By signing up you agree to our terms & conditions